# This Prostate Cancer Drug Works. Investors Think It Has the Wrong Partner. - Date: 2026-04-02 - Category: Biotech & Life Sciences The 84% five-month rPFS looks encouraging until you notice the data comes from just 18 patients, the comparator arm is darolutamide rather than a stronger AR inhibitor, and Wall Street sold off 27% anyway. ---